Erasmus School of Health Policy & Management
External PhD candidate | Health Technology Assessment (HTA)
- vellekoop@eshpm.eur.nl
More information
Work
- Heleen Vellekoop (2024) - The value of personalised medicine from a health economics perspective
- Irene Santi, Heleen Vellekoop, Matthijs M Versteegh, Simone A Huygens, Winand N.M. Dinjens & Maureen Rutten van Mölken (2024) - Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The Netherlands - Molecular Diagnosis and Therapy, 28 (3), 319-328 - doi: 10.1007/s40291-024-00704-2 - [link]
- Rositsa Koleva-Kolarova, Heleen Vellekoop, Matthijs Versteegh, Maureen van Molken, László Szilberhorn, Tamás Zelei, Balázs Nagy, Sarah Wordsworth & Apostolos Tsiachristas (2023) - Budget impact and transferability of cost–effectiveness of DPYD testing in metastatic breast cancer in three health systems - Personalized Medicine, 20 (4), 357-374 - doi: 10.2217/pme-2022-0133 - [link]
- László Szilberhorn, Tamás Zelei, Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, Maureen van Molken, Rositsa Koleva-Kolarova, Apostolos Tsiachristas, Sarah Wordsworth & Balázs Nagy (2023) - Cost–effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countries - Personalized Medicine, 20 (4), 387-399 - doi: 10.2217/pme-2023-0017 - [link]
- Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, László Szilberhorn, Tamás Zelei, Balázs Nagy, Rositsa Koleva-Kolarova, Sarah Wordsworth, Maureen Rutten-van Mölken & (2023) - Cost-effectiveness of alternative <i>NTRK </i>testing strategies in cancer patients followed by histology-independent therapy with entrectinib: an analysis of three European countries - Personalized Medicine, 20 (4), 321-338 - doi: 10.2217/pme-2022-0070 - [link]
- Rositsa Koleva-Kolarova, Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, Maureen van Molken, László Szilberhorn, Tamás Zelei, Balázs Nagy, Sarah Wordsworth & Apostolos Tsiachristas (2023) - Cost–effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK - Personalized Medicine, 20 (4), 339-355 - doi: 10.2217/pme-2022-0099 - [link]
- Gábor Kovács, Dávid Nagy, László Szilberhorn, Tamás Zelei, Zsolt Gaál, Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, Maureen Rutten van Mölken, Rositsa Koleva-Kolarova, Apostolos Tsiachristas, Sarah Wordsworth & Balázs Nagy (2023) - Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young - Personalized Medicine, 20 (4), 375-385 - doi: 10.2217/pme-2023-0023 - [link]
- Rositsa Koleva-Kolarova, László Szilberhorn, Tamás Zelei, Heleen Vellekoop, Balázs Nagy, Simone Huygens, Matthijs Versteegh, Maureen Rutten van Mölken, Sarah Wordsworth & Apostolos Tsiachristas (2023) - Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation - Personalized Medicine, 20 (4), 305-319 - doi: 10.2217/pme-2022-0145 - [link]
- Balázs Nagy, Tamás Zelei, Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, Maureen van Molken, Rositsa Koleva-Kolarova, Apostolos Tsiachristas, Sarah Wordsworth & László Szilberhorn (2023) - Lessons learned from the application of the HEcoPerMed guidance to three modeling case studies - Personalized Medicine, 20 (4), 401-411 - doi: 10.2217/pme-2023-0040 - [link]
- , Simone Huygens, Heleen Vellekoop, Matthijs Versteegh, Irene Santi, László Szilberhorn, Tamás Zelei, Balázs Nagy, Apostolos Tsiachristas, Rositsa Koleva-Kolarova, Sarah Wordsworth & Maureen Rutten-van Mölken (2023) - Cost-Effectiveness Analysis of Treating Patients With NTRK-Positive Cancer With the Histology-Independent Therapy Entrectinib - Value in Health, 26 (2), 193-203 - doi: 10.1016/j.jval.2022.08.006 - [link]
